Newsstand | Page 2 | Aplastic Anemia & MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option

Originally Published: 10/27/2020
Cryopreservation of grafts has been established in autologous and cord blood transplantation, yet there is little experience regarding the effect of cryopreservation with sibling and unrelated grafts. We evaluated the effect of cryopreservation of grafts on allogeneic transplant outcomes using related, unrelated and haploidentical donors, including 958 patients, age 18‐74 years (median 55) and using PBSC for various hematologic malignancies. Fresh grafts were received by 648 (68%) patients, 310 (32%) received cryopreserved. There was no difference between fresh vs cryopreserved grafts for...

Does Cancer Chemotherapy Increase My Covid Risks?

Originally Published: 10/07/2020
By Mikkael A. Sekeres, M.D. Oct. 7, 2020 Q. I have cancer and am being treated with chemotherapy. Am I at increased risk of getting sick and dying from Covid-19? A. People with cancer, and particularly those with leukemia, seem to have a higher death rate from Covid-19 than the general population, though cancer chemotherapy does not appear to further increase the risk of dying from Covid. Studies, however, have been limited and results are sometimes difficult to interpret. Many types of chemotherapy work by disrupting the cancer cell’s machinery that allows it to divide and grow so rapidly...

Rogue Antibodies and Gene Mutations Explain Some Cases of Severe COVID-19

Originally Published: 10/06/2020
One of the many perplexing issues with COVID-19 is that it affects people so differently. That has researchers trying to explain why some folks bounce right back from the virus, or don’t even know they have it—while others become critically ill. Now, two NIH-funded studies suggest that one reason some otherwise healthy people become gravely ill may be previously unknown trouble spots in their immune systems, which hamper their ability to fight the virus. According to the new findings in hundreds of racially diverse people with life-threatening COVID-19, a small percentage of people who...

Foundation Update Newsletter September 2020

Originally Published: 09/22/2020

Treatment Approaches in AML: Key Testing for Personalized Care

Originally Published: 09/16/2020
VIDEO  Description:  Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo. When it comes to Acute Myeloid Leukemia (AML), genetic testing (or biomarker testing) is essential in helping to determine the best treatment approach for YOU. In this program, AML expert, Dr. Naval Daver reviews key decision-making factors, current AML treatments and emerging research for patients with AML. Dr. Naval Daver is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.   Watch the video and read the...

Researchers describe impact of SF3B1 mutations in myelodysplastic syndrome

Originally Published: 09/14/2020
SF3B1 mutations occurred more frequently in de novo myelodysplastic syndromes than therapy-related myelodysplastic syndrome, according to results of a phase 2 study presented at Society of Hematologic Oncology Annual Meeting. Additionally, SF3B1 mutations appeared associated with improved survival among patients with de novo vs. therapy-related myelodysplastic syndrome (MDS). However, among patients with treatment-related disease, those with SF3B1 mutations had better outcomes than those with wild-type SF3B1. (Article and Charts continue at link)

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

Originally Published: 09/08/2020
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative. Chetasi Talati, MD Chetasi Talati, MD Early data suggest that the low-intensity combination of venetoclax (Venclexta) and hypomethylating agents (HMAs) may be a “game-changer” for patients with relapsed/refractory acute myeloid leukemia (AML), according to Chetasi Talati, MD, especially for older patients who may not...

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

Originally Published: 09/01/2020
On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. Efficacy was investigated in QUAZAR (NCT01757535), a multicenter, randomized, double-blind, placebo-controlled trial. Patients (n=472) who achieved CR or CRi with intensive induction chemotherapy with or without...

Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes

Originally Published: 09/01/2020
Abstract Background Little is known about the shared decision-making between patients with transfusion-dependent (TD) myelodysplastic syndromes (MDS) and their physicians about the benefits, risks, and alternatives to reduce the need for blood transfusions. Methods and Materials We conducted interviews and two cross-sectional surveys of MDS patients and MDS physicians in the US about the use of blood transfusions and disease-modifying therapies (DMTs). Responses from 157 MDS patients and 109 MDS physicians were analyzed. Results (continued at link)